Medication and behavioral therapy for meth abuse.
Steven Shoptaw, PhD is a licensed psychologist and Director of the Center for Behavioral and Addiction Medicine at UCLA. Also, he is a Professor in the UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences and is Vice Chair of Research in Family Medicine. Dr. Shoptaw has a portfolio of work that focuses on the treatment of addiction and HIV prevention in the context of addiction in the Western U.S. where stimulant use is the single strongest predictor of HIV transmission. For over 20 years, Dr. Shoptaw has conducted a series of clinical studies in community clinic settings, primarily on topics that involve the development of medical and behavioral interventions to treat substance abusers. Dr. Shoptaw recently completed a Phase I interaction safety study of ibudilast at relevant doses of methamphetamine and is Co-Investigator on a Phase II randomized controlled trial of ibudilast as an outpatient treatment for methamphetamine dependence. Dr. Shoptaw is also Principal Investigator of a Phase II study of Varenicline for methamphetamine dependence and was the Director of a NIDA-funded Center of Excellence on medication development for methamphetamine abuse (P50DA018185). Dr. Shoptaw is a member of the DAIDS-funded, HIV Prevention Trials Network (HPTN) Executive Committee, and site Principal Investigator for HPTN-073, a feasibility study of Pre-Exposure Prophylaxis (Truvada) in Black men who have sex with men. Additionally, Dr. Shoptaw is a Co-PI on a 5-year NIDA-funded cooperative agreement (U01 DA036267) to establish a cohort of minority men who have sex with men to investigate interactions between non-injection use of methamphetamine, cocaine, opiates and binge drinking and transmission and progression of HIV (ôM-Study). As the Director for the Combination Prevention Core for the UCLA Center for HIV Identification Prevention and Treatment Services, Dr. Shoptaw works with a team of colleagues to develop funded research on application of the next generation of technological advances (e.g., using cell phones, Internet) and biomedical approaches (microbicides, stem cells) to preventing HIV transmission. He is also Director of a T32 Training Program on Addiction Medicine in Primary Care funded by the National Institute on Drug Abuse. Dr. Shoptaw eagerly seeks out opportunities to mentor new investigators interested in academic careers along these topics and has mentored more than twenty pre- and post-doctoral students.
1. Shoptaw Steven, Heinzerling Keith G, Rotheram-Fuller Erin, Steward Trevor, Wang Jason, Swanson Aimee-Noelle, De La Garza Richard, Newton Tom, Ling Walter Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.. Drug and Alcohol Dependence. 2008; 96(3): 222-32.
2. Yang Xiaowei, Li Jinhui, Shoptaw Steven Imputation-based strategies for clinical trial longitudinal data with nonignorable missing values.. Statistics in Medicine. 2008; 27(15): 2826-49.
3. Shoptaw Steven, Reback Cathy J., Larkins Sherry, Wang Jason, Rotheram-Fuller Erin, Dang Jeff, Yang Xiaowei Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men.. Journal of Substance Abuse Treatment. 2008; 27(15): .
4. Nyamathi Adeline, Dixon Elizabeth L, Shoptaw Steven, Marfisee Mary, Gelberg Lillian, Williams Stephanie, Dominick Stephanie, Leake Barbara Profile of lifetime methamphetamine use among homeless adults in Los Angeles.. Drug and Alcohol Dependence. 2008; 92(1-3): 277-81.
5. King William, Larkins Sherry, Hucks-Ortiz Christopher, Wang Jason, Gorbach Pamina, Veniegas Rosemary, Shoptaw Steven Factors Associated with HIV Viral Load in a Respondent Driven Sample in Los Angeles.. AIDS and behavior. 2007; 92(1-3):.
6. Xiaowei Yang, Shoptaw Steven, Kun Nie, Juanmei Liu, Belin Thomas R Markov transition models for binary repeated measures with ignorable and nonignorable missing values.. Statistical methods in medical research. 2007; 16(4): 347-64.
Link to a complete list of my PubMed publications.